Upadacitinib: 16 agencies, 2019–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
PHARMAC (New Zealand) has been easier on upadacitinib than on its own caseload: it refused 0 of 9 decisive submissions here (0%), against a base rate of 29% across everything it has assessed.
Assessment has run over 7.1 years, from 2019 at PBAC (Australia) to 10 Aug 2026 at SMC (Scotland).
NYE METODER (Norway) changed its position: recommended on 30 Aug 2020, not recommended by 24 Aug 2025.
No assessment is on file from HAS (France), which is among the eight highest-volume agencies here.
The file is active: 44 of 93 records date from 2023 or later.
The programme is broad: 30 distinct indication wordings are recorded for upadacitinib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
13 of these 93 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess upadacitinib, in 2019; ZIN (Netherlands) did not open a file until 1 Mar 2024 — a wide spread of 4.7 years between the earliest and latest system to look at it.
The record arrives in waves: 7 separate years each carry two or more decisions, spread across 8 years in total.
13 of the 16 agencies here assessed upadacitinib more than once, PBAC (Australia) most often at 13 entries — repeat review is the norm for this molecule rather than the exception.
upadacitinib has been through 16 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for upadacitinib reads 45 recommended, 18 restricted, 10 not recommended and 7 deferred to NICE, with 13 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AOTMIT (Poland) | 9 Jul 2026 | programu lekowego B.75. „Leczenie pacjentów z układowymi zapaleniami naczyń (ICD-10: M30.1, M31.3, M31.5, M31.6, M31.7, … | recommended conditionally | source |
| PBAC (Australia) | 2026 | Fistulising Crohn’s disease (FCD) | Recommended | source |
| CIPM (Spain) | 17 Dec 2025 | Indicaciones terapéuticas autorizadas: Nota: Rinvoq 15 mg, 30 mg y 45 mg (comprimidos de liberación prolongada) tienen u… | not financed by the SNS · art. 92 d | source |
| ZIN (Netherlands) | 12 Dec 2025 | Advies - niet vergoeden upadacitinib (Rinvoq®) voor de behandeling van ontstoken bloedvaten | not reimbursed (sluis) | source |
| DMC (Denmark) | 24 Apr 2024 | Behandling af aktiv non-radiografisk aksial spondyloartritis (nr-axSpA) hos voksne patienter, som har responderet utilst… | Ikke anbefalet | source |
88 further decisions for upadacitinib, across 16 agencies, are not shown here. They include the most recent record on file, 10 Aug 2026 from SMC (Scotland); its outcome is in the subscriber dataset. They link to 75 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
- lenalidomide — same ATC class L04A — Immunosuppressants
Coverage: 93 decisions for upadacitinib from 16 agencies, 2019 to 2026. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.